VR Logo

Kaleido Biosciences Inc. (KLDO) download report


Healthcare | Biotechnology & Pharma Research

Kaleido Biosciences Inc. (KLDO) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies.

IPO Date: 28-Feb-2019

Sr. VP of Technical Operations: Ms. Kimberly Hocknell

Chief Regulatory Affairs ? Advisor: Ms. Susan Stewart J.D.

Listing: NASDAQ: KLDO

Country: United States

Headquarters: Lexington, MA

Website: https://kaleido.com

Key Facts

Market cap: $2.82 Mln

Revenue (TTM): $0.81 Mln

Earnings (TTM): $-67.25 Mln

Cash: $38.47 Mln

Total Debt: $16.14 Mln

Insider's Holding: 0.73%

Liquidity: Low

52 Week range: $0.04 - 8.25

Shares outstanding: 42,622,600

6 Years Aggregate:

  • CFO: $-292.57 Mln
  • EBITDA: $-342.71 Mln
  • Net Profit: $-357.23 Mln

Stock Performance

Time Period Kaleido Biosciences (KLDO) S&P BSE Sensex S&P Small-Cap 600
YTD-97.03-9.49-17.79
1 month26.56-2.87-2.72
3 months-95.99-8.59-12.17
1 Year-98.980.81-15.82
3 Years-82.3710.397.14
5 Years--11.116.20
10 Years--12.0010.33
As on 24-Jun-2022
Year Kaleido Biosciences (KLDO) S&P Small-Cap 600 S&P BSE Sensex
2021-73.7425.2721.99
202081.279.5715.75